Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease – Primary Biliary Cholangitis (PBC), a rare condition with high unmet medical needs.
Apparently, all the hype is not making Genfit lazy. It has just announced that it will diversify the diseases targeted by Elafibranor with a new trial in primary biliary cholangitis (PBC).
PBC is a chronic disease that causes the bile ducts to become inflamed, gradually destroying them. Bile ducts are a sort of internal plumbing to carry bile (which is secreted in the liver) to the intestine, where it is essential for food digestion.
The current treatment for PBC is ursodeoxycholic acid (UDCA), which replaces bile acids. But around 70% of the patients don’t tolerate or don’t respond sufficiently to this therapy –